sfRowasa (Ulcerative Colitis) – Forecast and Market Analysis to 2022

During the forecast period from 2012–2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Each sfRowasa unit is a 60mL rectal suspension that delivers up to 4g of mesalamine to the left side of the colon. sfRowasa sulfite-free (sf) formulation is the first sulfite-free rectal suspension available for the treatment of UC. The results of a study published in the American Journal of Gastroenterology in 1998 showed that products containing sulfites may be the cause of a possible flare in UC patients (Levine et al, 1998, Year). Hydrogen sulfide is a luminally-acting, bacterially-derived molecule that is harmful to cells and has been implicated in UC.


Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on SfRowasa including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for SfRowasa from 2012 to 2022.

Sales information covered for the US

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of SfRowasa performance

Obtain sales forecast for SfRowasa from 2012-2022 in the US

Table of Contents

1Table of Contents1

1.1List of Tables3

1.2List of Figures3

2Executive Summary4

2.1Sales for sfRowasa in Global UC Market, 2012–20224

2.2What Do Physicians Think?6



3.2Related Reports8

3.3Upcoming Related Reports10

4Disease Overview10

4.1Etiology and Pathophysiology10




4.2.1Quality of Life17

5Disease Management17

5.1Diagnosis and Treatment Overview17


5.1.2Treatment Guidelines and Leading Prescribed Drugs21

5.1.3Clinical Practice23

6Competitive Assessment26


6.2Strategic Competitor Assessment28

7sfRowasa (mesalamine)29




7.4SWOT Analysis30






8.4Forecasting Methodology37

8.4.1Diagnosed UC Patients37

8.4.2Percent Drug-Treated Patients38

8.4.3General Pricing Assumptions38

8.4.4Individual Drug Assumptions39

8.4.5Generic Erosion39

8.5Physicians and Specialists Included in This Study40

8.6Primary Research – Prescriber Survey42

8.7About the Authors43


8.7.2Global Head of Healthcare43

8.8About GlobalData44

8.9Contact Us44


List of Tables

Table 1: sfRowasa: Key Metrics in the 10MM UC Markets, 2012–20225

Table 2: Genetic Factors That Confer a Predisposition to UC13

Table 3: Typical Symptoms of UC15

Table 4: Truelove and Witts UC Severity Index19

Table 5: UCDAI20

Table 6: Treatment Guidelines for UC Used in the 10MM21

Table 7: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 201322

Table 8: Leading Treatments for UC, 201428

Table 9: Product Profile – sfRowasa29

Table 10: sfRowasa SWOT Analysis, 201430

Table 11: Global Sales Forecasts ($m) for sfRowasa, 2012–202230

Table 12: Annual Cost of Therapy for 5-ASAs ($)38

Table 13: Physicians Surveyed, By Country41

List of Figures

Figure 1: Sales for sfRowasa by Region, 2012-20226

Figure 2: Cellular Mechanisms Involved in the Pathogenesis of UC15

Figure 3: UC Disease Management Flowchart25


Discounts available for multiple report purchases.
+44 (0) 161 359 5813

Join our mailing list

Saved reports